[go: up one dir, main page]

PE20090291A1 - Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas - Google Patents

Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas

Info

Publication number
PE20090291A1
PE20090291A1 PE2008000856A PE2008000856A PE20090291A1 PE 20090291 A1 PE20090291 A1 PE 20090291A1 PE 2008000856 A PE2008000856 A PE 2008000856A PE 2008000856 A PE2008000856 A PE 2008000856A PE 20090291 A1 PE20090291 A1 PE 20090291A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
glutamatergal
disustituted
amidas
Prior art date
Application number
PE2008000856A
Other languages
English (en)
Inventor
Rudolf Mueller
Steven Lee
Leslie J Street
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40122059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of PE20090291A1 publication Critical patent/PE20090291A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, EN EL QUE W ES O, S O CH=CH; X, Y y Z SON -N O -CR; R ES H, -Br, -Cl, -NO2, F=O, ENTRE OTROS; A ES H O ALQUILO(C1-C6), ALQUILCICLOALQUILO(C3-C7), ENTRE OTROS; n ES DE 0 A 6; E ES CICLOALQUILO(C3-C7), AZACICLOALQUILO(C4-C7), BICICLOALQUILO(C7-C10), ENTRE OTROS; B ES -C=, C-Ra, O, N, S, C=O, S=O O SO2; Ra ES H, HALOGENO, CIANO, ENTRE OTROS; D NO ESTA PRESENTE CUANDO B ES O, S, S=O, C=O O SO2, Y SI ESTA PRESENTE, ESTA UNIDO A B CUANDO B ES -C=, -C-Ra O N Y ES H, ORb, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; Rb ES H, ALQUILO(C1-C7) O ACILO(C2-C7). SON SELECCIONADOS N-CICLOHEXIL-N-METIL-[2,1,3]-BENZOXADIAZOL-5-CARBOXAMIDA, CLORHIDRATO DE TRANS-4-[(2,1,3-BENZOXADIAZOL-5-ILCARBONIL)(METIL)AMINO]CICLOHEXIL GLICINATO, ENTRE OTROS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DE 0.5 A 75% DEL PESO TOTAL EN PRINCIPIO ACTIVO. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES AMPA, IMPORTANTES EN EL MEJORAMIENTO DE LA RESPUESTA SINAPTICA GLUTAMATERGICA, POR LO QUE SON DE UTILIDAD EN EL TRATAMIENTO DE FUNCION COGNITIVA DETERIORADA, ESQUIZOFRENIA, PARKINSON, SINDROME DE RETT, ALZHEIMER, ENTRE OTROS
PE2008000856A 2007-05-17 2008-05-19 Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas PE20090291A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93063307P 2007-05-17 2007-05-17
US95806907P 2007-07-02 2007-07-02

Publications (1)

Publication Number Publication Date
PE20090291A1 true PE20090291A1 (es) 2009-03-19

Family

ID=40122059

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000856A PE20090291A1 (es) 2007-05-17 2008-05-19 Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas

Country Status (17)

Country Link
US (3) US8013003B2 (es)
EP (1) EP2154970B1 (es)
JP (1) JP5694765B2 (es)
KR (2) KR20100017687A (es)
CN (1) CN101742911A (es)
AR (1) AR066641A1 (es)
AU (1) AU2008254960B2 (es)
CA (1) CA2685858C (es)
CL (1) CL2008001465A1 (es)
EA (1) EA200901546A1 (es)
ES (1) ES2657054T3 (es)
IL (1) IL202187A0 (es)
MX (1) MX2009012430A (es)
NZ (1) NZ582035A (es)
PE (1) PE20090291A1 (es)
TW (1) TW200911768A (es)
WO (1) WO2008143963A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616592B (zh) * 2007-01-03 2013-06-05 瑟维尔实验室 用于提高谷氨酸能突触响应的3-取代的-[1,2,3]-苯并三嗪酮化合物
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
TW200911768A (en) * 2007-05-17 2009-03-16 Cortex Pharma Inc Di-substituted amides for enhancing glutamatergic synaptic responses
US8263591B2 (en) * 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
WO2010087981A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
CN106164059A (zh) * 2014-04-11 2016-11-23 爱默蕾大学 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2018009256A1 (en) * 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN115448892B (zh) * 2022-09-19 2023-07-07 郑州铁路职业技术学院 一种苯并噻二唑杂环化合物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
DK1156043T3 (da) * 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer
US20020099050A1 (en) 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
FR2710065B1 (fr) * 1993-09-13 1996-10-04 Smithkline Beecham Labo Pharma Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments.
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
WO1998011892A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
SE9904765D0 (sv) * 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
KR20010016247A (ko) * 2000-11-27 2001-03-05 구현사 광고 및 전자상거래를 위한 웹브라우징 어플리케이션
AUPS255202A0 (en) 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
WO2005000793A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２位置換シクロアルキルカルボン酸誘導体
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
NZ619746A (en) * 2003-08-06 2014-05-30 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
EP1675830A4 (en) * 2003-09-30 2008-08-20 Scios Inc HETEROCYCLIC AMIDES AND SULFONAMIDES
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP2589599B1 (en) * 2004-03-03 2014-06-25 Takeda GmbH Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
US8173642B2 (en) * 2005-10-25 2012-05-08 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives
JP2007291087A (ja) * 2006-03-29 2007-11-08 Taisho Pharmaceut Co Ltd ピリジン誘導体及びその使用に関連する治療法
EP2114158B1 (en) * 2007-01-03 2012-08-08 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
CN101616592B (zh) 2007-01-03 2013-06-05 瑟维尔实验室 用于提高谷氨酸能突触响应的3-取代的-[1,2,3]-苯并三嗪酮化合物
TW200911768A (en) * 2007-05-17 2009-03-16 Cortex Pharma Inc Di-substituted amides for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
EP2195303A4 (en) 2007-09-20 2011-07-20 Cortex Pharma Inc 3-SUBSTITUTED 1,2,3-TRIAZIN-4-ONE AND 3-SUBSTITUTED 1,3-PYRIMIDIONE FOR INCREASING GLUTAMATERGIC SYNAPTIC REACTIONS

Also Published As

Publication number Publication date
US8404682B2 (en) 2013-03-26
US20100120764A1 (en) 2010-05-13
CN101742911A (zh) 2010-06-16
CA2685858C (en) 2015-11-24
JP2010527359A (ja) 2010-08-12
IL202187A0 (en) 2010-06-16
MX2009012430A (es) 2010-01-14
US8013003B2 (en) 2011-09-06
EA200901546A1 (ru) 2010-04-30
WO2008143963A1 (en) 2008-11-27
AU2008254960A1 (en) 2008-11-27
TW200911768A (en) 2009-03-16
ES2657054T3 (es) 2018-03-01
AU2008254960B2 (en) 2014-11-27
EP2154970A4 (en) 2011-03-30
NZ582035A (en) 2012-03-30
US20130137733A1 (en) 2013-05-30
EP2154970B1 (en) 2017-10-25
US8642633B2 (en) 2014-02-04
CL2008001465A1 (es) 2009-09-25
US20120035173A1 (en) 2012-02-09
JP5694765B2 (ja) 2015-04-01
CA2685858A1 (en) 2008-11-27
KR20100017687A (ko) 2010-02-16
KR101599661B1 (ko) 2016-03-03
KR20140129360A (ko) 2014-11-06
EP2154970A1 (en) 2010-02-24
AR066641A1 (es) 2009-09-02

Similar Documents

Publication Publication Date Title
PE20090291A1 (es) Amidas disustituidas para mejorar las respuestas sinapticas glutamatergicas
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
BRPI0411528A (pt) uso de isomalte como prebiótico
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
GT200500185A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
ECSP067025A (es) DERIVADOS DE TETRAAZABENZO [e] AZULENO Y SUS ANÁLOGOS
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
MXPA06002880A (es) Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes.
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
NO20090910L (no) Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
MA34078B1 (fr) Derives d'arylethynyle
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
PA8759501A1 (es) Formas cristalinas
AR071925A1 (es) Malonamidas como antagonistas de orexina
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
HN2009001067A (es) Antagonistas de receptor de orexina de diazepan sustituido
SV2008003032A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
NI201000011A (es) Derivados de pirimidina 934.
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed